(Q36205831)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Genetic factors influencing pyrimidine-antagonist chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Maring JG

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Groen HJ

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Wachters FM

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Uges DR

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

The Pharmacogenomics Journal

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

226-243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16041392%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500320

4 January 2020

exact match

0 references

cites work

Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

A systematic overview of chemotherapy effects in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Approaches to induction therapy with adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Fluorouracil: biochemistry and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Fluorouracil and the new oral fluorinated pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Polymorphism of uridine monophosphate kinase: population study in Japanese and phenotyping in bloodstains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase pharmacogenetics in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Forced expression of cytidine deaminase confers sensitivity to capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Genetic basis of hemolytic anemia caused by pyrimidine 5' nucleotidase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Increased dihydropyrimidine dehydrogenase activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Low expression of the deoxycytidine kinase (dCK) gene in a 1-beta-D-arabinofuranosylcytosine-resistant human leukemic cell line KY-Ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

Adjuvant therapy of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Preclinical characteristics of gemcitabine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Novel thymidylate synthase enhancer region alleles in African populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Conversion of 5-formyltetrahydrofolic acid to 5-methyltetrahydrofolic acid is unimpaired in folate-adequate persons homozygous for the C677T mutation in the methylenetetrahydrofolate reductase gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Known variant DPYD alleles do not explain DPD deficiency in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021

Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500320

7 January 2021